Clinical Trial Update: Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for iparomlimab and tuvonralimab in MSI-H gastric/gastroesophageal junction adenocarcinoma; the study is currently not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Peking University | Conditions: Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer | Phase 2 | Status: NOT_YET_RECRUITING